

# OSTEOARTHRITIS IN 2011: MANY STEPS TO CLIMB

*Osteoarthritis is a primary disorder of hyaline cartilage that results in secondary changes in subchondral bone and eventually joint failure.*

## **BRIDGET HODKINSON, MB BCH, FCP (SA), CERT RHEUM**

*Physician and Rheumatologist, Division of Rheumatology, Department of Medicine, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand, Johannesburg*

*Bridget Hodkinson's research interests include early rheumatoid arthritis and osteoarthritis. She has recently returned from a 9-month Pfizer Articularum fellowship in the Hand Osteoarthritis Unit of St-Antoine Hospital, Paris. Clinical research during this time included aesthetic damage assessments in hand osteoarthritis, and clinical aspects of erosive osteoarthritis.*

## **MOHAMMED TIKLY, MB BCH, MMED, FRCP, FCP (SA), PHD**

*Professor and Head, Division of Rheumatology, Department of Internal Medicine, University of the Witwatersrand, Johannesburg*

*Mohammed Tikly is based at Chris Hani Baragwanath Academic Hospital, Soweto. He completed his undergraduate training at Wits and trained in rheumatology at the University of Edinburgh, Scotland. His special interests are outcomes and genetics of rheumatic diseases in South Africans.*

*Correspondence to: Bridget Hodkinson (drbridget@gmail.com)*

### References

1. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. *Ann Rheum Dis* 2001;60:91-97.
2. Spector TD, et al. Genetic influences on osteoarthritis in women: a twin study. *BMJ* 1996;312:940-943.
3. Valdes AM, Spector TD. The genetic epidemiology of osteoarthritis. *Curr Opin Rheumatol* 2010;22:139-143.
4. Anderson JJ, Felson DT. Factors associated with osteoarthritis of the knee in the first national Health and Nutrition Examination Survey (HANES I). Evidence for an association with overweight, race, and physical demands of work. *Am J Epidemiol* 1988;128:179-189.
5. Toda Y, et al. Change in body fat, but not body weight or metabolic correlates of obesity, is related to symptomatic relief of obese patients with knee osteoarthritis after a weight control program. *J Rheumatol* 1998;25:2181-2186.
6. Adebajo AO. Osteoarthritis. *Baillieres Clin Rheumatol*, 1995;9(1):65-74.
7. Gibbon VE, et al. Mseleni joint disease: a potential model of epigenetic chondrodysplasia. *Joint Bone Spine* 2010;77:399-404.
8. Yach D, Botha JL. Mseleni joint disease in 1981: decreased prevalence rates, wider geographical location than before, and socioeconomic impact of an endemic osteoarthrosis in an underdeveloped community in South Africa. *Int J Epidemiol* 1985;14:276-284.
9. Gibbon VE, et al. Mseleni joint disease: a potential model of epigenetic chondrodysplasia. *Joint Bone Spine* 2010;77:399-404.
10. Kwan Tat S, et al., Targeting subchondral bone for treating osteoarthritis: what is the evidence? *Best Pract Res Clin Rheumatol* 2010;24:51-70.
11. Rannou F, et al. Splint for base-of-thumb osteoarthritis: a randomized trial. *Ann Intern Med* 2009;150:661-669.
12. Mejjad O, Serrie A, Ganry H. Epidemiological data, efficacy and safety of a paracetamol-tramadol fixed combination in the treatment of moderate-to-severe pain. SALZA: a post-marketing study in general practice. *Curr Med Res Opin* 2011;27:1013-1020.
13. Tramer MR, et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. *Pain* 2000;85:169-182.
14. Chan FK, et al. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. *Am J Gastroenterol* 2008;103:2908-2918.
15. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. *JAMA* 2006;296:1633-1644.
16. Baraf HS, et al. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three randomized, double-blind, parallel-group, placebo-controlled, multicentre trials. *Drugs Aging* 2011;28:27-40.
17. Schnitzer TJ. New pharmacologic approaches in the management of osteoarthritis. *Arthritis Care Res (Hoboken)* 2010;62:1174-1180.
18. Bruyere O, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. *Osteoarthritis Cartilage* 2008;16:254-260.
19. Gigante A, Callegari L. The role of intra-articular hyaluronan (Sinovial) in the treatment of osteoarthritis. *Rheumatol Int* 2011;31:427-444.
20. Berenbaum F. Targeted therapies in osteoarthritis: a systematic review of the trials on [www.clinicaltrials.gov](http://www.clinicaltrials.gov). *Best Pract Res Clin Rheumatol* 2010;24:107-119.

# CURRENT DIAGNOSIS AND TREATMENT STRATEGIES IN RHEUMATOID ARTHRITIS

*Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that preferentially targets the synovial lining of the joints but can affect other organ systems including the lungs, heart and blood vessels.*

**AYANDA GCELU, MB ChB, FCP(SA), Cert Rheum (SA)**

*Consultant in Rheumatology and Internal Medicine, University of Cape Town and Groote Schuur Hospital*

*Ayanda Gcelu worked as a Community Service Medical Officer at George Hospital, then worked in various hospitals in the UK as a Senior House Officer in Accidents and Emergencies and Paediatrics. He obtained the FCP in 2005 and worked as a Consultant in Medical Emergencies and Internal Medicine at GF Jooste Hospital for 2 years. In 2008 he moved back to Groote Schuur Hospital and worked as a Registrar in Rheumatology and obtained the Certificate in Rheumatology in 2009.*

**ASGAR ALI KALLA, MB ChB, FCP (SA), MD, FRCP (Lond)**

*Professor of Rheumatology, Department of Medicine, University of Cape Town*

*Asgar Kalla's research interests include osteoporosis in rheumatic diseases, disease activity and disability assessment in rheumatoid arthritis, monitoring of disease modification in rheumatoid arthritis, toxicity profiles of slow-acting anti-rheumatic drugs, NSAID gastropathy and mechanisms of bone loss in rheumatic diseases.*

*Correspondence to: Ayanda Gcelu agcelu@yahoo.com*

## References

1. Nam J, Combe B, Emery P. Early arthritis: diagnosis and management. Eular On-Line Course on Rheumatic Diseases. [www.eular-onlinecourse.org](http://www.eular-onlinecourse.org).
2. Eshed I, Feist E, Althoff CE, et al. Early rheumatoid arthritis – do we really know what it means? Consistency and distribution of MRI findings according to different definitions for early rheumatoid arthritis. *Clin Rheumatol* 2011;30:551-555.
3. Allaart CF, Huizinga TWJ. Treatment strategies in recent onset rheumatoid arthritis. *Curr Opin Rheumatol* 2011;23: 241-244.
4. Aletaha D, Neogi T, Silman A, et al. Rheumatoid Arthritis Classification Criteria. *Arthritis Rheum* 2010; 62(9): 2569-2581.
5. Meyer O, Labarre C, Dougadas M, et al. Anti citrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting 5-year radiographic damage. *Ann Rheum Dis* 2003;62(2):120-126.
6. Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. *Curr Opin Rheumatol* 2011;23:245-251.

# ARTICULAR SYNDROMES IN ASSOCIATION WITH HIV INFECTION

*Although articular manifestations as a result of HIV infection, apart from arthralgia, are uncommon, they may result in considerable morbidity.*

**GIRISH M MODY, MB ChB, FCP (SA), MD, FRCP (Lond)**

*Aaron Family Professor and Head, Department of Rheumatology, Nelson R Mandela School of Medicine, University of KwaZulu-Natal and Inkosi Albert Luthuli Central Hospital, Durban*

*Girish Mody is a Past-President of the South African Rheumatism and Arthritis Association and the African League of Associations for Rheumatology and served as an Executive Committee member of the International League of Associations for Rheumatology. He serves as Associate Editor for Clinical Rheumatology and is a member of the editorial board for Best Practice and Research in Clinical Rheumatology. His research interests include HIV and arthritis, genetics of rheumatoid arthritis and systemic lupus erythematosus.*

**NEETA PATEL, MB ChB, FCP (SA)**

*Principal Specialist and Lecturer, Department of Rheumatology, Nelson R Mandela School of Medicine, University of KwaZulu-Natal and Inkosi Albert Luthuli Central Hospital*

*Neeta Patel is a Consultant in the Department of Rheumatology, involved in teaching undergraduates, postgraduates and allied health professionals. She is a Fellow of the College of Physicians of South Africa, involved in the examination of candidates for the fellowship examinations in the College of Medicine of South Africa. Her research interests include haematological abnormalities in lupus and rheumatological manifestations of HIV infection.*

*Correspondence to: Girish Mody (modyg@ukzn.ac.za )*

## References

1. Nguyen BY, Reveille JD. Rheumatic manifestations associated with HIV in the highly active antiretroviral era. *Curr Opin Rheumatol* 2009;21(4):404-410.
2. Louthrenoo W. Rheumatic manifestations of human immunodeficiency virus infection. *Curr Opin Rheumatol* 2008;20(1):92-99.
3. Walker UA, Tyndall A, Daikeler T. Rheumatic conditions in human immunodeficiency virus infection. *Rheumatology* 2008;47(7):952-959.
4. Reveille JD, Williams FM. Rheumatologic complications of HIV infection. *Best Pract Res Clin Rheumatol* 2006;20(6):1159-1179.
5. Calabrese LH, Kirchner E, Shresatha R. Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. *Semin Arthritis Rheum* 2005;35(3):166-174.
6. Mody GM, Parke FA, Reveille JD. Articular manifestations of human immunodeficiency virus infection. *Best Pract Res Clin Rheumatol* 2003;17(2):265-287.
7. Cuellar ML, Espinoza LR. Rheumatic manifestations of HIV-AIDS. *Bailliere's Best Pract Res Clin Rheumatol* 2000;14(3):579-593.
8. Njobvu P, McGill P. Human immunodeficiency virus related reactive arthritis in Zambia. *J Rheumatol* 2005;32(7):1299-1304.
9. Njobvu P, McGill P. Psoriatic arthritis and human immunodeficiency virus infection in Zambia. *J Rheumatol* 2000;27(7):1699-1702.
10. Njobvu P, McGill P, Kerr H, et al. Spondyloarthropathy and human immunodeficiency virus infection. *J Rheumatol* 1998;25(8):1553-1559.
11. Dougadas M, van der Linden S, Juhlin R, et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. *Arthritis Rheum* 1991;34(10):1218-1227.
12. Ntsiba H, Ngandeu-Singwe M, Makita-Bagamboula, C, et al. Human Immunodeficiency Virus associated arthritis in Congo Brazzaville. *Med Mal Infect* 2007;37(11):758-761.
13. Mary-Krause M, Billaud E, Poizot-Martin I, et al. Risk factors for osteonecrosis in HIV infected patients: impact of treatment with combination antiretroviral therapy. *AIDS* 2006;20(12):1627-1635.
14. Ho YC, Shih TT, Lin YH, et al. Osteonecrosis in patients with human immunodeficiency virus type 1 infection in Taiwan. *Jpn J Infect Dis* 2007;60(6):382-386.
15. Chinniah K, Mody GM, Bhimma R, Adhikari M. Arthritis in association with human immunodeficiency virus infection in black African children : causal or coincidental? *Rheumatology* 2005;44(7):1-6.

# CLINICAL EVALUATION AND DIAGNOSIS OF CONNECTIVE TISSUE DISEASES

*Connective tissue diseases present in many different ways and their diagnosis can be challenging.*

**MOHAMED AMIN MAKDA, MB BCh, FCP (SA), Cert Rheum (SA)**

*Division of Rheumatology, Department of Medicine, Chris Hani Baragwanath Hospital, University of the Witwatersrand, Johannesburg*

*Mohamed Makda is Consultant Physician/Rheumatologist at the Chris Hani Baragwanath Academic Hospital, Soweto. He did undergraduate and postgraduate training at the University of the Witwatersrand. His special interests are musculoskeletal ultrasonography and systemic lupus erythematosus.*

**MOHAMMED TIKLY, MB BCh, MMed, FRCP, FCP (SA), PhD**

*Professor and Head, Division of Rheumatology, Department of Internal Medicine, University of the Witwatersrand, Johannesburg*

*Mohammed Tikly is based at Chris Hani Baragwanath Academic Hospital, Soweto. He completed his undergraduate training at Wits and trained in rheumatology at the University of Edinburgh, Scotland. His special interests are outcomes and genetics of rheumatic diseases in South Africans.*

*Correspondence to: Mohamed Makda (mamakda@telkomsa.net)*

## References

1. Alarcon GS. Unclassified or undifferentiated connective tissue disease. Baillieres Best Pract Res Clin Rheumatol 2000;14:125-137.
2. Gould T, Tikly M. Systemic lupus erythematosus in a patient with human immunodeficiency virus infection - challenges in diagnosis and management. Clin Rheumatol 2004;23:166-169.
3. Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res 2009;30:99-105.
4. Kavanaugh AF, Solomon DH. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum 2002;47:546-555.

# ESSENTIALS OF MUSCULOSKELETAL EXAMINATION

*Many doctors feel uncomfortable when examining the musculoskeletal system.*

**ASGAR ALI KALLA, MB ChB, FCP (SA), MD, FRCP (Lond)**

*Professor of Rheumatology, Department of Medicine, University of Cape Town*

*Asgar Kalla's research interests include osteoporosis in rheumatic diseases, disease activity and disability assessment in rheumatoid arthritis, monitoring of disease modification in rheumatoid arthritis, toxicity profiles of slow-acting anti-rheumatic drugs, NSAID gastropathy and mechanisms of bone loss in rheumatic diseases.*

*Correspondence to: Asgar Kalla (kallaa@iafrica.com)*

## References

1. Abou-Ray A, Abou-Raya S. The inadequacies of musculoskeletal education. *Clin Rheumatol* 2010;29:1121-1126.
2. Dequeker J, Rasker JJ, Woolf AD. Educational issues in rheumatology. *Best Pract Res Clin Rheumatol* 2000;14:715-729.
3. Woolf AD, Akesson K. Understanding the burden of musculoskeletal conditions. The burden is huge and not reflected in national health priorities. *BMJ* 2001;322(294):1079-1080.
4. Schmale GA. More evidence of educational inadequacies in musculoskeletal medicine. *Clin Orthop* 2005;437:251-259.
5. Doherty M, Hazleman BL, Hutton CW, Maddison PJ, Perry JD. *Rheumatology examination and injection techniques*. London: WB Saunders, 1992.
6. Doherty M, Dacre J, Dieppe P, Snaith M. The 'GALS' locomotor screen. *Ann Rheum Dis* 1992;51:1165-1169.
7. Mody GM, Tikly M, Kalla AA, Meyers OL. Approach to arthritis: Clinical guidelines. *S Afr Med J* 2003;99:949-962.
8. Aletaho D, Neogi J, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria. *Arthritis Rheum* 2010; 62:2569-2581.

# MORE ABOUT...RHEUMATOLOGY

## The eye in rheumatoid arthritis

**N DU TOIT, MB ChB, DipOph (SA), FRCS (Edin), FCOPh (SA), MMed**

*Consultant Ophthalmic Surgeon/Senior Lecturer, Division of Ophthalmology, Department of Surgery, Groote Schuur Hospital and University of Cape Town*

*Correspondence to: N Du Toit (ndutoit@mweb.co.za)*

### References

1. Zltanaovic G, Veselinovic D, et al. Ocular manifestation of rheumatoid arthritis – different forms and frequency. *Bosn J Basic Med Sci* 2010;10(4):323-327.
2. Papis SA, Tsonis IA, Moutsopoulos HM. Sjögren's syndrome. *Semin Respir Crit Care Med* 2007;28(4):459-471.
3. Sutphin JE, Chodosh J, et al. Immune-related disorders of the external eye. In: Liesegang TJ, ed. *Basic and Clinical Science Course – External Disease and Cornea*. San Francisco, Calif.: American Academy of Ophthalmology 2004:193-228.
4. Squirrell DM, Winfield J, Amos RS. Peripheral ulcerative keratitis 'corneal melt' and rheumatoid arthritis: a case series. *Rheumatology* 1999;38(12):1245-1248.
5. Kanski JJ. Cornea. In: Kanski JJ, ed. *Clinical Ophthalmology*. Woburn, Mass: Butterworth-Heinemann 2007:278-281.

## Upper limb pain syndromes

**MAHMOOD MOOSA TAR MAHOMED ALLY, MB BCh, FCP (SA)**

*Professor and Head, Division of Rheumatology, Department of Internal Medicine, School of Medicine, University of Pretoria*

*Correspondence to: M Ally (tar@up.ac.za)*

### References

1. Parshant A, Bharti A, Dinesh J. Clinical approach to neck pain. *Indian J Rheumatol* 2010;5(4):193-198.
2. Walker-Bone KE, Palmer KT, Reading I, Cooper C. Criteria for assessing pain and nonarticular soft-tissue rheumatic disorders of the neck and upper limb. *Semin Arthritis Rheum* 2003;33(3):168-184.
3. Fouquet B. Clinical examination as a tool for identifying the origin of regional musculoskeletal pain. *Best Pract Res Clin Rheumatol* 2003;17(1):1-15.
4. Baring T, Emery R, Reilly P. Management of rotator cuff disease: specific treatment for specific disorders. *Best Pract Res Clin Rheumatol* 2007;21(2):279-294.
5. Farid N, Bruce D, Chung CB. Miscellaneous conditions of the shoulder: Anatomical, clinical, and pictorial review emphasizing potential pitfalls in imaging diagnosis. *Eur J Radiol* 2008;68:88-105.
6. D'Agostino MM, Olivieri I. Enthesitis. *Best Pract Res Clin Rheumatol* 2006;20(3):473-486.
7. Palmer KT. Pain in the forearm, wrist and hand. *Best Pract Res Clin Rheumatol* 2003;17(1):113-135.
8. Ankarath S. Chronic wrist pain: Diagnosis and management. *Current Orthopaedics* 2006;20:141-151.

## Fibromyalgia

**NEETA PATEL, MB ChB, FCP (SA)**

*Principal Specialist and Lecturer, Department of Rheumatology, Nelson R Mandela School of Medicine, University of KwaZulu-Natal and Inkosi Albert Luthuli Central Hospital, Durban*

**GIRISH M MODY, MB ChB, FCP (SA), MD, FRCP (Lond), Fellow of the University of KwaZulu-Natal**

*Aaron Family Professor and Head of the Department of Rheumatology, Nelson R Mandela School of Medicine, University of KwaZulu-Natal and Inkosi Albert Luthuli Central Hospital, Durban*

*Correspondence to: N Patel (pateln2@ukzn.ac.za)*

### References

1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee. *Arthritis Rheum* 1990;33(2):160-172.
2. Buskila D. Developments in the scientific and clinical understanding of fibromyalgia. *Arth Res Ther* 2009;1(5):242.
3. Winfield JB. Fibromyalgia. *emedicine Rheumatology* 2009. <http://emedicine.medscape.com/article/329839-overview>
4. Wolfe F, Clauw WD, Fitzcharles M, et al. The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. *Arth Care Res* 2010;62(5):600-610.
5. Goldenberg DL. Comprehensive assessment of fibromyalgia and overlapping conditions. *Am J Med* 2009;122:S14-S21

## Use of biological agents in rheumatic disease

**ELSA VAN DUUREN, *BMedSci, MB ChB, MSc (Sports Medicine), MMed (Med Phys)***  
*Rheumatologist, Jacaranda Hospital, Pretoria*

Correspondence to: [evduuren@mweb.co.za](mailto:evduuren@mweb.co.za)

### References

1. Tutuncu Z, Kavanaugh A. Anticytokine therapies. Kelley's Textbook of Rheumatology. 7th ed. Elsevier Saunders, 2005:940-950.
2. Keystone EC, Strand V. Emerging therapies in rheumatoid arthritis. Kelley's Textbook of Rheumatology. 7th ed. Elsevier Saunders, 2005:951-960.
3. Furst DE, Keystone E, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. *Ann Rheum Dis* 2011;70(Suppl 1):i2- i36.

## Gout – an overview

**B J JANSEN VAN RENSBURG, *MB ChB, MMed (INT), FCP (SA)***

*Subspecialist in Rheumatology and Clinical Head, Rheumatology, Department of Internal Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein*

Correspondence to: [B J Jansen van Rensburg \(gninbjvr@ufs.ac.za\)](mailto:gninbjvr@ufs.ac.za)

### References

1. Aaron TE. Gout: An update. *Am Fam Physician* 2007;76(6):801-808.
2. Becker MA, Ruoff GE. What do I need to know about gout? *J Fam Pract* 2010;59 (6): S1-S8.
3. Popa-Nita O, Naccache PH. Crystal-induced neutrophil activation. *Immunol Cell Biol* 2010;88:32-40 (Suppl.).
4. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis* 2006;65:1301-1311.
5. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis* 2006; 65:1312-1324.
6. Hoskison TK, Wortmann RL. Advances in the management of gout and hyperuricaemia. *Scand J Rheumatol* 2006;35:251-260.
7. Pittman JR, Bross MH. Diagnosis and management of gout. *Am Fam Physician* 1999;59(7):1799-1806.
8. Schlesinger N. Dietary factors and hyperuricaemia. *Curr Pharm* 2005;11:4133-4138.
9. Yang LPH. Oral colchicine (Colcrys®) in the treatment and prophylaxis of gout. *Drugs* 2010;70(12):1603-1613.
10. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. *Current Pharmaceutical Design* 2005;11:4161-4175.

## Lower limb pain syndromes

**MAHMOOD MOOSA TAR MAHOMED ALLY, *MB BCh, FCP (SA)***

*Professor and Head, Division of Rheumatology, Department of Internal Medicine, School of Medicine, University of Pretoria*

**FARHANA EBRAHIM SULEMAN, *MB BCh, MMed Rad (D)UL, FCRad (D) SA***

*Senior Specialist, Department of Radiology, School of Medicine, University of Pretoria*

Correspondence to: [M Ally \(tar@up.ac.za\)](mailto:M Ally (tar@up.ac.za))

### References

1. Argoff CE, Wheeler AH. Spinal and radicular pain disorders. *Neurol Clinics* 1998;16(4):833-845.
2. Lloyd RFW, Feeney C. Adolescent hip pain: the needle in the haystack. A case report. *Physiotherapy* 2011, doi:10.1016/j.physio.2010.11.009.
3. Zacher J, Gursche A. "Hip" pain. *Best Practice and Research Clinical Rheumatology* 2003;7(1):71-85.
4. Plante M, Wallace R, BD Busconi. Clinical diagnosis of hip pain. *Clin Sports Med* 2011;30:225-238.
5. Llopis E, Mario P. Anterior knee pain. *Eur J Radiol* 2007;62:27-43.
6. Bálint GP. Foot and ankle disorders. *Best Practice and Research Clinical Rheumatology* 2003;17(1):87-111.

## The lungs in the rheumatic diseases

**ISMAIL S KALLA, MB BCh, FCP (SA), FCCP (USA), Cert Pulmonology (SA), Cert Critical Care (SA)**  
*Pulmonologist/intensivist, Department of Pulmonology and Critical Care, University of the Witwatersrand, Johannesburg*

*Correspondence to: I S Kalla (isk786@telkomsa.net)*

### References

1. Lam G, Petri M. Assessment of systemic lupus erythematosus. *Clin Exp Rheumatol* 2005;23:S120-S132.
2. Ante LR, Wyatt JP. Roentgenological and pathological observations in antigenic pneumonitis, its relationship to the collagen diseases. *AJR Am J Roentgenol Radium Ther Nucl Med* 1951;66:527-545.
3. Ooi GC, Ngan H, Peh WC, et al. Systemic lupus erythematosus patients with respiratory symptoms: the value of HRCT. *Clin Radiol* 1997;52:775-781.
4. Bodolay E, Szekanecz Z, Devenyi K, et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). *Rheumatology (Oxford)* 2005;44:656-661.
5. Ryu JH, Bongartz T, Matteson EL. Interstitial lung disease in connective tissue diseases: what are the important questions? *Arthritis Rheum* 2005;53:488-490.
6. Bertolaccini ML, Khamashta MA. Laboratory diagnosis and management challenges in the antiphospholipid syndrome. *Lupus* 2006;15:172-178.
7. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. *Eur Respir J* 2000;15:373-381.